Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Claytons research contributions to PT-141 development include: Principal investigator for pivotal Phase 2 dose-finding trial establishing optimal 1.75 mg dose Lead investigator for RECONNECT Phase 3 trials supporting FDA approval Development of responder analysis methodology for patient-reported outcomes in sexual dysfunction Neurobehavioral research elucidating central mechanisms of sexual desire Extensive publication record on bremelanotide efficacy, safety, and clinical applications Her work has established PT-141 as the second FDA-approved pharmacological treatment for HSDD and the first melanocortin-based therapy for sexual dysfunction, representing a significant advance in womens sexual health treatment options
Eagle H, Oyama VI, Levy M, Horton CL,Fleischman R
IMPORTANT NOTE: This situation is quickly and constantly changing and will likely continue to do so
A personalised treatment plan will be discussed at your initial consultation
In addition, unbiased studies of combinations of treatment options for supplements, including large cohort clinical trials, will lead to evidence-based medicine
The first observable signal is typically reduced hair loss not a surface treatment, a signaling shift
US$ 27.85
US$ 22.10
US$ 22.17
US$ 20.10
US$ 28.26
